company background image
ELDN

Eledon Pharmaceuticals NasdaqCM:ELDN Stock Report

Last Price

US$2.51

Market Cap

US$34.5m

7D

-5.6%

1Y

-51.5%

Updated

25 Nov, 2022

Data

Company Financials +
ELDN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ELDN Stock Overview

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant.

Eledon Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eledon Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.51
52 Week HighUS$5.32
52 Week LowUS$2.27
Beta1.85
1 Month Change2.03%
3 Month Change-32.35%
1 Year Change-51.54%
3 Year Change-78.97%
5 Year Change-96.72%
Change since IPO-97.81%

Recent News & Updates

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Sep 06

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Aug 31
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Recent updates

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Aug 31
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14
Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21
What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Shareholder Returns

ELDNUS BiotechsUS Market
7D-5.6%0.4%1.3%
1Y-51.5%-14.4%-18.5%

Return vs Industry: ELDN underperformed the US Biotechs industry which returned -13.5% over the past year.

Return vs Market: ELDN underperformed the US Market which returned -20.2% over the past year.

Price Volatility

Is ELDN's price volatile compared to industry and market?
ELDN volatility
ELDN Average Weekly Movement8.7%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: ELDN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ELDN's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a12DA Groshttps://eledon.com

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021.

Eledon Pharmaceuticals, Inc. Fundamentals Summary

How do Eledon Pharmaceuticals's earnings and revenue compare to its market cap?
ELDN fundamental statistics
Market CapUS$34.53m
Earnings (TTM)-US$38.39m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ELDN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$38.39m
Earnings-US$38.39m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.79
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ELDN perform over the long term?

See historical performance and comparison